EE200400003A - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents
Pyrrolopyrimidines as protein kinase inhibitorsInfo
- Publication number
- EE200400003A EE200400003A EEP200400003A EEP200400003A EE200400003A EE 200400003 A EE200400003 A EE 200400003A EE P200400003 A EEP200400003 A EE P200400003A EE P200400003 A EEP200400003 A EE P200400003A EE 200400003 A EE200400003 A EE 200400003A
- Authority
- EE
- Estonia
- Prior art keywords
- pyrrolopyrimidines
- protein kinase
- kinase inhibitors
- inhibitors
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
US30167801P | 2001-06-28 | 2001-06-28 | |
PCT/GB2002/002835 WO2003000695A1 (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200400003A true EE200400003A (en) | 2004-02-16 |
EE05432B1 EE05432B1 (en) | 2011-06-15 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200400003A EE05432B1 (en) | 2001-06-23 | 2002-06-21 | P rrolop rimidines as protein kinase inhibitors |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (en) |
JP (1) | JP4344607B2 (en) |
CN (1) | CN1294135C (en) |
AU (1) | AU2002314325B8 (en) |
BR (1) | BR0210652A (en) |
CA (1) | CA2451932C (en) |
CZ (1) | CZ20033443A3 (en) |
EA (1) | EA007415B1 (en) |
EC (1) | ECSP034922A (en) |
EE (1) | EE05432B1 (en) |
GB (1) | GB0115393D0 (en) |
HU (1) | HUP0400300A3 (en) |
ME (1) | MEP19308A (en) |
NZ (1) | NZ529766A (en) |
OA (1) | OA12632A (en) |
PL (1) | PL374096A1 (en) |
RS (1) | RS51698B (en) |
SK (1) | SK15882003A3 (en) |
TN (1) | TNSN03144A1 (en) |
TR (1) | TR200302242T2 (en) |
UA (1) | UA76760C2 (en) |
WO (1) | WO2003000695A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
AU2003265336B8 (en) | 2002-07-29 | 2009-04-23 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
JP2007511596A (en) * | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | Pyrrolopyrimidine compounds useful in the treatment of cancer |
EP1689407A1 (en) * | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
US20050250829A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Kinase inhibitors |
FR2876103B1 (en) | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
FR2878849B1 (en) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
ES2612196T3 (en) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors |
MX2009003793A (en) | 2006-10-09 | 2009-12-14 | Takeda Pharmaceutical | Kinase inhibitors. |
EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
AU2009211004C1 (en) | 2008-01-11 | 2013-08-01 | Natco Pharma Limited | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
WO2009152133A1 (en) | 2008-06-10 | 2009-12-17 | Abbott Laboratories | Novel tricyclic compounds |
TWI484962B (en) | 2009-05-22 | 2015-05-21 | Incyte Corp | 3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)octane-or heptane-nitrile as jak inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
SI2506716T1 (en) | 2009-12-01 | 2017-10-30 | Abb Vie Inc. | Novel tricyclic compounds |
KR102354472B1 (en) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
JP5917544B2 (en) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
CN103476776B (en) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor |
CN102093364B (en) | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor |
JP5876146B2 (en) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors |
TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
CN104662018B (en) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | Substituted Heterobicyclic compounds, composition and its medical applications |
AR091079A1 (en) | 2012-05-18 | 2014-12-30 | Incyte Corp | DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS |
HUE033294T2 (en) | 2012-07-26 | 2017-11-28 | Glaxo Group Ltd | 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors |
US10227357B2 (en) | 2012-09-06 | 2019-03-12 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
HUE055894T2 (en) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
PE20151902A1 (en) | 2013-03-06 | 2015-12-26 | Incyte Corp | PROCESS AND INTERMEDIATES TO MAKE A JAK INHIBITOR |
US9650358B2 (en) | 2013-03-13 | 2017-05-16 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
WO2014159999A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Cdk9 kinase inhibitors |
WO2014139328A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
US9346813B2 (en) | 2013-03-14 | 2016-05-24 | Abbvie Inc. | Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors |
MX2015012896A (en) | 2013-03-14 | 2016-06-02 | Abbvie Inc | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors. |
EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
CN104804001B9 (en) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
BR122022024925B1 (en) | 2015-10-16 | 2023-11-28 | Abbvie Inc | PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION COMPRISING (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROL[2,3-E]PYRAZIN-8-IL)-N-(2,2 ,2-TRIFLUOROETHYL) PYRROLI-DINE-1-CARBOXAMIDE |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
BR112019018576A2 (en) | 2017-03-09 | 2020-04-14 | Abbvie Inc | methods of treating crohn's disease and ulcerative colitis |
AR113922A1 (en) | 2017-12-08 | 2020-07-01 | Incyte Corp | LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS |
DK3746429T3 (en) | 2018-01-30 | 2022-05-02 | Incyte Corp | PROCEDURES FOR THE PREPARATION OF (1- (3-FLUORO-2- (TRIFLUOROMETHYL) ISONICOTINYL) PIPERIDIN-4-ON) |
IL277538B1 (en) | 2018-03-30 | 2024-05-01 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
FI3860998T3 (en) | 2018-10-05 | 2024-03-27 | Annapurna Bio Inc | Compounds and compositions for treating conditions associated with apj receptor activity |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT888349E (en) * | 1996-01-23 | 2002-10-31 | Novartis Ag | PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION |
IL129825A0 (en) * | 1996-11-27 | 2000-02-29 | Pfizer | Fused bicyclic pyrimidine derivatives |
PA8474101A1 (en) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
CZ20004727A3 (en) * | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Derivatives of pyrrolo[2,3-d]pyrimidine |
TR200101395T2 (en) * | 1998-09-18 | 2001-11-21 | Basf Ag. | 4-Aminopyrrolopyrimidines as kinase inhibitors |
MXPA02005675A (en) * | 1999-12-10 | 2002-09-02 | Pfizer Prod Inc | PYRROLO[2,3 d]PYRIMIDINE COMPOUNDS. |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 EA EA200400073A patent/EA007415B1/en not_active IP Right Cessation
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/en unknown
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/en unknown
- 2002-06-21 EP EP02740895A patent/EP1404676A1/en not_active Withdrawn
- 2002-06-21 CA CA002451932A patent/CA2451932C/en not_active Expired - Fee Related
- 2002-06-21 EE EEP200400003A patent/EE05432B1/en not_active IP Right Cessation
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/en active Application Filing
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/en not_active Application Discontinuation
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/en unknown
- 2002-06-21 CN CNB028119320A patent/CN1294135C/en not_active Expired - Fee Related
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/en unknown
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/en not_active Expired - Fee Related
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/en not_active Application Discontinuation
- 2002-06-21 PL PL02374096A patent/PL374096A1/en not_active Application Discontinuation
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 UA UA2004010502A patent/UA76760C2/en unknown
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/en unknown
Also Published As
Publication number | Publication date |
---|---|
RS99203A (en) | 2006-12-15 |
CA2451932C (en) | 2009-12-29 |
AU2002314325B2 (en) | 2009-01-08 |
JP2005508300A (en) | 2005-03-31 |
RS51698B (en) | 2011-10-31 |
CN1294135C (en) | 2007-01-10 |
TR200302242T2 (en) | 2004-12-21 |
ECSP034922A (en) | 2004-04-28 |
WO2003000695A1 (en) | 2003-01-03 |
EA007415B1 (en) | 2006-10-27 |
NZ529766A (en) | 2008-11-28 |
EE05432B1 (en) | 2011-06-15 |
HUP0400300A2 (en) | 2007-08-28 |
UA76760C2 (en) | 2006-09-15 |
EP1404676A1 (en) | 2004-04-07 |
SK15882003A3 (en) | 2004-07-07 |
BR0210652A (en) | 2004-08-10 |
JP4344607B2 (en) | 2009-10-14 |
HUP0400300A3 (en) | 2010-12-28 |
CZ20033443A3 (en) | 2004-03-17 |
EA200400073A1 (en) | 2004-08-26 |
CN1518552A (en) | 2004-08-04 |
PL374096A1 (en) | 2005-09-19 |
AU2002314325B8 (en) | 2009-01-29 |
GB0115393D0 (en) | 2001-08-15 |
MEP19308A (en) | 2010-06-10 |
WO2003000695A8 (en) | 2004-03-11 |
OA12632A (en) | 2006-06-14 |
CA2451932A1 (en) | 2003-01-03 |
TNSN03144A1 (en) | 2005-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200400003A (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
HK1068134A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
AU2003254053A8 (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
NO20041887L (en) | Benzomidazoles useful as protein kinase inhibitors | |
EP1510210A4 (en) | Immunity-related protein kinase inhibitors | |
DE60129794D1 (en) | PYRROL SUBSTITUTED INDOLIN-2-ON PROTEIN KINASE INHIBITORS | |
DE60128709D1 (en) | TRIAZOL COMPOUNDS AS PROTEIN KINASE INHIBITORS | |
NO20011356D0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
EE200200140A (en) | Pteridinones as kinase inhibitors | |
IL173380A0 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
HK1078491A1 (en) | Cyclic protein tyrosine kinase inhibitors | |
ID30460A (en) | INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN | |
AU2002334355A1 (en) | Protein tyrosine kinase inhibitors | |
ATE505471T1 (en) | AZAINDOL KINASE INHIBITORS | |
DE60119776D1 (en) | PYRAZOL COMPOUNDS AS PROTEIN KINASE INHIBITORS | |
IS6968A (en) | New tyrosine kinase inhibitors | |
DK1370553T3 (en) | Rho kinase inhibitors | |
DK1370552T3 (en) | Rho kinase inhibitors | |
ATE255114T1 (en) | TRICYCLIC PROTEIN KINASE INHIBITORS | |
AU2002953255A0 (en) | Protein kinase inhibitors | |
AUPS251502A0 (en) | Protein kinase inhibitors | |
IL151779A0 (en) | Protein tyrosine kinase inhibitors | |
IL145329A0 (en) | Protein tyrosine kinase inhibitors | |
AU2002953385A0 (en) | Protein kinase inhibitors | |
AU2002953330A0 (en) | Protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20120621 |